

# Dan G Duda

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/988615/publications.pdf>

Version: 2024-02-01

256  
papers

30,296  
citations

5876

81  
h-index

4870

168  
g-index

267  
all docs

267  
docs citations

267  
times ranked

33324  
citing authors

#	ARTICLE	IF	CITATIONS
1	Placental growth factor promotes tumour desmoplasia and treatment resistance in intrahepatic cholangiocarcinoma. <i>Gut</i> , 2022, 71, 185-193.	6.1	34
2	Abstract P061: Dendritic cell paucity in mismatch repair-proficient colorectal cancer liver metastases limits the efficacy of immune checkpoint blockade. , 2022, , .		0
3	Leveraging Blood-Based Diagnostics to Predict Tumor Biology and Extend the Application and Personalization of Radiotherapy in Liver Cancers. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1926.	1.8	1
4	Combining p53 mRNA nanotherapy with immune checkpoint blockade reprograms the immune microenvironment for effective cancer therapy. <i>Nature Communications</i> , 2022, 13, 758.	5.8	94
5	Predictive Modeling of Survival and Toxicity in Patients With Hepatocellular Carcinoma After Radiotherapy. <i>JCO Clinical Cancer Informatics</i> , 2022, 6, e2100169.	1.0	0
6	Increased CD8+ T-cell Infiltration and Efficacy for Multikinase Inhibitors After PD-1 Blockade in Hepatocellular Carcinoma. <i>Journal of the National Cancer Institute</i> , 2022, 114, 1301-1305.	3.0	22
7	VCP interaction with HMGB1 promotes hepatocellular carcinoma progression by activating the PI3K/AKT/mTOR pathway. <i>Journal of Translational Medicine</i> , 2022, 20, 212.	1.8	12
8	Multiphoton Phosphorescence Quenching Microscopy Reveals Kinetics of Tumor Oxygenation during Antiangiogenesis and Angiotensin Signaling Inhibition. <i>Clinical Cancer Research</i> , 2022, 28, 3076-3090.	3.2	4
9	A Phase I Trial of TB-403 in Relapsed Medulloblastoma, Neuroblastoma, Ewing Sarcoma, and Alveolar Rhabdomyosarcoma. <i>Clinical Cancer Research</i> , 2022, 28, 3950-3957.	3.2	5
10	The Current Landscape of Immune Checkpoint Blockade in Hepatocellular Carcinoma. <i>JAMA Oncology</i> , 2021, 7, 113.	3.4	213
11	Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma. <i>Clinical Cancer Research</i> , 2021, 27, 1048-1057.	3.2	129
12	NASH limits anti-tumour surveillance in immunotherapy-treated HCC. <i>Nature</i> , 2021, 592, 450-456.	13.7	649
13	Toward Personalized Radiation Therapy of Liver Metastasis: Importance of Serial Blood Biomarkers. <i>JCO Clinical Cancer Informatics</i> , 2021, 5, 315-325.	1.0	5
14	Combining losartan with radiotherapy increases tumor control and inhibits lung metastases from a HER2/neu-positive orthotopic breast cancer model. <i>Radiation Oncology</i> , 2021, 16, 48.	1.2	19
15	Fatty acid synthesis is required for breast cancer brain metastasis. <i>Nature Cancer</i> , 2021, 2, 414-428.	5.7	147
16	Bevacizumab improves tumor infiltration of mature dendritic cells and effector T-cells in triple-negative breast cancer patients. <i>Npj Precision Oncology</i> , 2021, 5, 62.	2.3	23
17	Radiotherapy to Enhance Chimeric Antigen Receptor T-Cell Therapeutic Efficacy in Solid Tumors. <i>JAMA Oncology</i> , 2021, 7, 1051.	3.4	25
18	Nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer: a phase II and biomarker study. <i>Npj Breast Cancer</i> , 2021, 7, 110.	2.3	20

#	ARTICLE	IF	CITATIONS
19	Machine Learning for Future Subtyping of the Tumor Microenvironment of Gastro-Esophageal Adenocarcinomas. <i>Cancers</i> , 2021, 13, 4919.	1.7	5
20	Dendritic cell paucity in mismatch repair-proficient colorectal cancer liver metastases limits immune checkpoint blockade efficacy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	40
21	Changes in Blood Biomarkers of Angiogenesis and Immune Modulation after Radiation Therapy and Their Association with Outcomes in Thoracic Malignancies. <i>Cancers</i> , 2021, 13, 5725.	1.7	5
22	Abstract PO-097: Addition of losartan to FOLFIRINOX and chemoradiation reduces the expression of pro-invasive and immunosuppressive genes in locally-advanced pancreatic cancer. , 2021, , .		0
23	Tumor Microenvironment. , 2020, , 108-126.e7.		3
24	A phase II study of cabozantinib alone or in combination with trastuzumab in breast cancer patients with brain metastases. <i>Breast Cancer Research and Treatment</i> , 2020, 179, 113-123.	1.1	26
25	Bevacizumab Reduces Permeability and Concurrent Temozolomide Delivery in a Subset of Patients with Recurrent Glioblastoma. <i>Clinical Cancer Research</i> , 2020, 26, 206-212.	3.2	48
26	Dual Programmed Death Receptor-1 and Vascular Endothelial Growth Factor Receptor-2 Blockade Promotes Vascular Normalization and Enhances Antitumor Immune Responses in Hepatocellular Carcinoma. <i>Hepatology</i> , 2020, 71, 1247-1261.	3.6	247
27	Vascular dysfunction promotes regional hypoxia after bevacizumab therapy in recurrent glioblastoma patients. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa157.	0.4	8
28	Regorafenib combined with PD1 blockade increases CD8 T-cell infiltration by inducing CXCL10 expression in hepatocellular carcinoma. , 2020, 8, e001435.		87
29	Phase I and Biomarker Study of the Wnt Pathway Modulator DKN-01 in Combination with Gemcitabine/Cisplatin in Advanced Biliary Tract Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 6158-6167.	3.2	37
30	Going Beyond VEGF Pathway Inhibition for Antiangiogenic Cancer Therapy. <i>Circulation Research</i> , 2020, 127, 724-726.	2.0	1
31	Optimizing Radiation Therapy to Boost Systemic Immune Responses in Breast Cancer: A Critical Review for Breast Radiation Oncologists. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 227-241.	0.4	24
32	Potential Circulating Biomarkers of Recurrence after Hepatic Resection or Liver Transplantation in Hepatocellular Carcinoma Patients. <i>Cancers</i> , 2020, 12, 1275.	1.7	19
33	Antibody-mediated delivery of viral epitopes to tumors harnesses CMV-specific T cells for cancer therapy. <i>Nature Biotechnology</i> , 2020, 38, 420-425.	9.4	48
34	Combining microenvironment normalization strategies to improve cancer immunotherapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 3728-3737.	3.3	163
35	Overcoming sorafenib treatment-resistance in hepatocellular carcinoma: A future perspective at a time of rapidly changing treatment paradigms. <i>EBioMedicine</i> , 2020, 52, 102644.	2.7	8
36	Lack of Targetable FGFR2 Fusions in Endemic Fluke-Associated Cholangiocarcinoma. <i>JCO Global Oncology</i> , 2020, 6, 628-638.	0.8	35

#	ARTICLE	IF	CITATIONS
37	Immune checkpoint blockade (ICB) response evaluation with MRI/MR elastography (MRE) in surgical and nonsurgical patients with HCC.. Journal of Clinical Oncology, 2020, 38, 480-480.	0.8	2
38	Randomized, open-label, perioperative phase II study evaluating nivolumab alone or nivolumab plus ipilimumab in patients with resectable HCC.. Journal of Clinical Oncology, 2020, 38, 486-486.	0.8	6
39	IGF-Child-Turcotte-Pugh score as a predictor of treatment outcome in Child-Pugh A, advanced hepatocellular carcinoma patients undergoing sorafenib therapy.. Journal of Clinical Oncology, 2020, 38, e16660-e16660.	0.8	0
40	The role of ALBI and IGF-CTP score in refining prognostication of HCC.. Journal of Clinical Oncology, 2020, 38, e16659-e16659.	0.8	0
41	Treatment outcome and prognostic indicators in 26 cases of fibrolamellar hepatocellular carcinoma under interferon based therapy.. Journal of Clinical Oncology, 2020, 38, e16626-e16626.	0.8	0
42	IGF-1 Child-Turcotte-Pugh score as a predictor of overall survival to therapy in CTP-A, BCLC stage C patients with advanced hepatocellular carcinoma.. Journal of Clinical Oncology, 2020, 38, 488-488.	0.8	11
43	Multicenter, Prospective, Phase II and Biomarker Study of High-Dose Bevacizumab as Induction Therapy in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannoma. Journal of Clinical Oncology, 2019, 37, 3446-3454.	0.8	73
44	Phase II trial of ponatinib in patients with bevacizumabâ€refractory glioblastoma. Cancer Medicine, 2019, 8, 5988-5994.	1.3	23
45	Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer. JAMA Oncology, 2019, 5, 1020.	3.4	353
46	Inter-patient variations of radiation-induced normal-tissue changes in Gd-EOB-DTPA-enhanced hepatic MRI scans during fractionated proton therapy. Clinical and Translational Radiation Oncology, 2019, 18, 113-119.	0.9	1
47	Role of Apelin in Glioblastoma Vascularization and Invasion after Anti-VEGF Therapy: What Is the Impact on the Immune System?. Cancer Research, 2019, 79, 2104-2106.	0.4	15
48	FOLFOX plus zivâ€flibercept or placebo in firstâ€line metastatic esophagogastric adenocarcinoma: A doubleâ€blind, randomized, multicenter phase 2 trial. Cancer, 2019, 125, 2213-2221.	2.0	14
49	Synthetic mRNA nanoparticle-mediated restoration of p53 tumor suppressor sensitizes <i>p53</i>-deficient cancers to mTOR inhibition. Science Translational Medicine, 2019, 11, .	5.8	177
50	A Phase II and Biomarker Study of Sorafenib Combined with Modified FOLFOX in Patients with Advanced Hepatocellular Carcinoma. Clinical Cancer Research, 2019, 25, 80-89.	3.2	62
51	Dual endothelin receptor inhibition enhances T-DM1 efficacy in brain metastases from HER2-positive breast cancer. Npj Breast Cancer, 2019, 5, 4.	2.3	12
52	Changes in tumor vascularity depicted by contrast-enhanced EUS as a predictor of prognosis and treatment efficacy in patients with unresectable pancreatic cancer (PEACE): A study protocol. Endoscopic Ultrasound, 2019, 8, 235.	0.6	13
53	Anti-angiogenics and Radiation Therapy. , 2019, , 349-358.		0
54	Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nature Reviews Clinical Oncology, 2018, 15, 325-340.	12.5	1,192

#	ARTICLE	IF	CITATIONS
55	Differential Association Between Circulating Lymphocyte Populations With Outcome After Radiation Therapy in Subtypes of Liver Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 1222-1225.	0.4	29
56	Obesity promotes resistance to anti-VEGF therapy in breast cancer by up-regulating IL-6 and potentially FGF-2. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	153
57	Can smart nanomedicine deliver effective targeted cytotoxic treatments to hepatocellular carcinomas while reducing the liver damage?. <i>Hepatology</i> , 2018, 67, 826-828.	3.6	1
58	Combined Angiotensin Receptor Blocker Losartan and the CXCR4 Inhibitor AMD3100 Increases the Efficacy of Radiotherapy in a Metastatic Osteosarcoma Mouse Model. <i>Journal of Cancer Science &amp; Therapy</i> , 2018, 10, .	1.7	1
59	Probing tumor microenvironment in patients with newly diagnosed glioblastoma during chemoradiation and adjuvant temozolomide with functional MRI. <i>Scientific Reports</i> , 2018, 8, 17062.	1.6	11
60	Pretreatment plasma HGF as potential biomarker for susceptibility to radiation-induced liver dysfunction after radiotherapy. <i>Npj Precision Oncology</i> , 2018, 2, 22.	2.3	20
61	Phase I and Biomarker Study of Plerixafor and Bevacizumab in Recurrent High-Grade Glioma. <i>Clinical Cancer Research</i> , 2018, 24, 4643-4649.	3.2	37
62	Combined delivery of sorafenib and a MEK inhibitor using CXCR4-targeted nanoparticles reduces hepatic fibrosis and prevents tumor development. <i>Theranostics</i> , 2018, 8, 894-905.	4.6	72
63	Phase II trial of ponatinib in patients with bevacizumab-refractory glioblastoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 2032-2032.	0.8	2
64	A phase II study of nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer (mTNBC).. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS1119-TPS1119.	0.8	0
65	A phase II study of cabozantinib (cabo) alone or in combination with trastuzumab (T) in patients (pts) with breast cancer brain metastases (BCBM).. <i>Journal of Clinical Oncology</i> , 2018, 36, 1026-1026.	0.8	0
66	Overcoming sorafenib evasion in hepatocellular carcinoma using CXCR4-targeted nanoparticles to co-deliver MEK-inhibitors. <i>Scientific Reports</i> , 2017, 7, 44123.	1.6	56
67	A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma. <i>Cancer</i> , 2017, 123, 1979-1988.	2.0	92
68	The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	89
69	Use of inhibitors of the renin-angiotensin system is associated with longer survival in patients with hepatocellular carcinoma. <i>United European Gastroenterology Journal</i> , 2017, 5, 987-996.	1.6	49
70	Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?. <i>Angiogenesis</i> , 2017, 20, 185-204.	3.7	482
71	A cerebellar window for intravital imaging of normal and disease states in mice. <i>Nature Protocols</i> , 2017, 12, 2251-2262.	5.5	21
72	Early changes in glioblastoma metabolism measured by MR spectroscopic imaging during combination of anti-angiogenic cediranib and chemoradiation therapy are associated with survival. <i>Npj Precision Oncology</i> , 2017, 1, .	2.3	16

#	ARTICLE	IF	CITATIONS
73	Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma. <i>Cancer Discovery</i> , 2017, 7, 1116-1135.	7.7	637
74	Phase II study of tivozanib, an oral VEGFR inhibitor, in patients with recurrent glioblastoma. <i>Journal of Neuro-Oncology</i> , 2017, 131, 603-610.	1.4	69
75	Phase II and Biomarker Study of Cabozantinib in Metastatic Triple-Negative Breast Cancer Patients. <i>Oncologist</i> , 2017, 22, 25-32.	1.9	79
76	Oncolytic virus delivery: from nano-pharmacodynamics to enhanced oncolytic effect. <i>Oncolytic Virotherapy</i> , 2017, Volume 6, 39-49.	6.0	32
77	Nonalcoholic steatohepatitis-related hepatocellular carcinoma: is there a role for the androgen receptor pathway?. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 1403-1412.	1.0	5
78	New Perspective on the Treatment of Intractable Gastrointestinal Cancers: Role of Combination Therapies. <i>Keio Journal of Medicine</i> , 2017, 66, 72-72.	0.5	1
79	Anti-angiogenics and Radiation Therapy. , 2017, , 1-10.		2
80	Abstract PR06: VEGF-targeted therapy induces extracellular matrix remodeling and increases mechanical barriers to therapy in colorectal cancer liver metastases. , 2017, , .		0
81	Anti-VEGFR Therapy as a Partner for Immune-Based Therapy Approaches in HCC. , 2017, , 85-101.		0
82	Abstract 5008: The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation. , 2017, , .		0
83	Next generation metronomic chemotherapyâ€”report from the Fifth Biennial International Metronomic and Anti-angiogenic Therapy Meeting, 6â€”8 May 2016, Mumbai. <i>Ecancermedicalscience</i> , 2016, 10, 689.	0.6	10
84	A protein and mRNA expression-based classification of gastric cancer. <i>Modern Pathology</i> , 2016, 29, 772-784.	2.9	142
85	Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 4470-4475.	3.3	251
86	Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 4476-4481.	3.3	287
87	Exploration of Imaging Biomarkers for Predicting Survival of Patients With Advanced Nonâ€”Small Cell Lung Cancer Treated With Antiangiogenic Chemotherapy. <i>American Journal of Roentgenology</i> , 2016, 206, 987-993.	1.0	28
88	Tissue Microbiome Profiling Identifies an Enrichment of Specific Enteric Bacteria in <i>Opisthorchis viverrini</i> Associated Cholangiocarcinoma. <i>EBioMedicine</i> , 2016, 8, 195-202.	2.7	94
89	Reengineering the Tumor Microenvironment to Alleviate Hypoxia and Overcome Cancer Heterogeneity. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2016, 6, a027094.	2.9	119
90	Immune modulation by hypofractionated stereotactic radiation therapy: Therapeutic implications. <i>Radiotherapy and Oncology</i> , 2016, 120, 185-194.	0.3	99

#	ARTICLE	IF	CITATIONS
91	Anti-VEGF therapy induces ECM remodeling and mechanical barriers to therapy in colorectal cancer liver metastases. <i>Science Translational Medicine</i> , 2016, 8, 360ra135.	5.8	184
92	Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2 Associated Vestibular Schwannomas. <i>Journal of Clinical Oncology</i> , 2016, 34, 1669-1675.	0.8	92
93	PLGF/VEGFR-1 Signaling Promotes Macrophage Polarization and Accelerated Tumor Progression in Obesity. <i>Clinical Cancer Research</i> , 2016, 22, 2993-3004.	3.2	109
94	Rationally combining anti-VEGF therapy with checkpoint inhibitors in hepatocellular carcinoma. <i>Immunotherapy</i> , 2016, 8, 299-313.	1.0	124
95	Preclinical Efficacy of Ado-trastuzumab Emtansine in the Brain Microenvironment. <i>Journal of the National Cancer Institute</i> , 2016, 108, .	3.0	56
96	Abstract LB-346: Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages. , 2016, , .		1
97	Effect of cabozantinib treatment on circulating immune cell populations in patients with metastatic triple-negative breast cancer (TNBC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 1093-1093.	0.8	3
98	Circulating biomarkers in a phase II study of hypofractionated proton beam therapy (H-PBT) for hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 4083-4083.	0.8	1
99	Role of stromal cell-derived factor 1 pathway in bone metastatic prostate cancer. <i>Journal of Biomedical Research</i> , 2016, 30, 181-5.	0.7	11
100	Abstract B03: Formation of lymph node metastases is not angiogenesis dependent. , 2016, , .		0
101	Abstract LB-347: Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival. , 2016, , .		2
102	Texture Analysis of Non-Contrast-Enhanced Computed Tomography for Assessing Angiogenesis and Survival of Soft Tissue Sarcoma. <i>Journal of Computer Assisted Tomography</i> , 2015, 39, 607-612.	0.5	45
103	Lessons From 30 Years of Teaching About the Microenvironment of Tumors. <i>Cancer Journal (Sudbury, Tj ETQq1 1 0.784314 rgBT /Ov</i>	1.0	2
104	From the Guest Editors. <i>Cancer Journal (Sudbury, Mass )</i> , 2015, 21, 235-236.	1.0	6
105	Familial Gastric Cancers. <i>Oncologist</i> , 2015, 20, 1365-1377.	1.9	46
106	Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 14325-14330.	3.3	206
107	CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor immunotherapy in sorafenib-treated hepatocellular carcinoma in mice. <i>Hepatology</i> , 2015, 61, 1591-1602.	3.6	355
108	Quantum dot/antibody conjugates for in vivo cytometric imaging in mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 1350-1355.	3.3	109

#	ARTICLE	IF	CITATIONS
109	CT Perfusion as an Imaging Biomarker in Monitoring Response to Neoadjuvant Bevacizumab and Radiation in Soft-Tissue Sarcomas: Comparison With Tumor Morphology, Circulating and Tumor Biomarkers, and Gene Expression. <i>American Journal of Roentgenology</i> , 2015, 204, W11-W18.	1.0	23
110	Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 1547-1552.	3.3	115
111	Lessons From Anti-VEGF Vascular Endothelial Growth Factor and Anti-VEGF Vascular Endothelial Growth Factor Receptor Trials in Patients With Glioblastoma. <i>Journal of Clinical Oncology</i> , 2015, 33, 1197-1213.	0.8	145
112	Investigation of the Lack of Angiogenesis in the Formation of Lymph Node Metastases. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	3.0	97
113	Chemotherapy and antiangiogenics in biliary tract cancer. <i>Lancet Oncology</i> , The, 2015, 16, 882-883.	5.1	2
114	Micelle-Encapsulated Quantum Dot-Porphyrin Assemblies as <i>in Vivo</i> Two-Photon Oxygen Sensors. <i>Journal of the American Chemical Society</i> , 2015, 137, 9832-9842.	6.6	104
115	An orthotopic mouse model of hepatocellular carcinoma with underlying liver cirrhosis. <i>Nature Protocols</i> , 2015, 10, 1264-1274.	5.5	82
116	A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients. <i>Clinical Cancer Research</i> , 2015, 21, 3610-3618.	3.2	79
117	Reply to Ciccolini et al.: Using mathematical modeling to predict response to antiangiogenic therapy in cancer patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E3454-E3454.	3.3	0
118	A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma. <i>Neuro-Oncology</i> , 2015, 17, 1386-1392.	0.6	50
119	Vascular diseases await translation of blood vessels engineered from stem cells. <i>Science Translational Medicine</i> , 2015, 7, 309rv6.	5.8	24
120	Targeting immunosuppression after standard sorafenib treatment to facilitate immune checkpoint blockade in hepatocellular carcinoma – an auto-commentary on clinical potential and future development. <i>OncImmunology</i> , 2015, 4, e1029703.	2.1	9
121	Phase I study of plerixafor and bevacizumab in recurrent high-grade glioma. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS2080-TPS2080.	0.8	1
122	A Phase II study of cabozantinib for metastatic triple-negative breast cancer (TNBC). <i>Journal of Clinical Oncology</i> , 2015, 33, 1080-1080.	0.8	2
123	Abstract B79: CXCR4 inhibition facilitates anti-PD-1 immunotherapy by reprogramming the tumor microenvironment during sorafenib treatment in hepatocellular carcinoma. , 2015, , .		0
124	Seeds and Soil: Unraveling the Role of Local Tumor Stroma in Distant Metastasis. <i>Journal of the National Cancer Institute</i> , 2014, 106, dju187-dju187.	3.0	8
125	Characterization of Functional Transient Receptor Potential Melastatin 8 Channels in Human Pancreatic Ductal Adenocarcinoma Cells. <i>Pancreas</i> , 2014, 43, 795-800.	0.5	19
126	Differential effects of sorafenib on liver versus tumor fibrosis mediated by stromal-derived factor 1 alpha/C-X-C receptor type 4 axis and myeloid differentiation antigen-positive myeloid cell infiltration in mice. <i>Hepatology</i> , 2014, 59, 1435-1447.	3.6	178



#	ARTICLE	IF	CITATIONS
127	Radiation-induced changes in hepatocyte-specific Gd-EOB-DTPA enhanced MRI: Potential mechanism. <i>Medical Hypotheses</i> , 2014, 83, 477-481.	0.8	13
128	Immune checkpoint blockade in hepatocellular carcinoma: Current progress and future directions. <i>Hepatology</i> , 2014, 60, 1776-1782.	3.6	210
129	A Phase 1/2 and Biomarker Study of Preoperative Short Course Chemoradiation With Proton Beam Therapy and Capecitabine Followed By Early Surgery for Resectable Pancreatic Ductal Adenocarcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 89, 830-838.	0.4	101
130	Vascular and Interstitial Biology of Tumors. , 2014, , 108-126.e5.		3
131	Phase I study of plerixafor and bevacizumab in recurrent high-grade glioma.. <i>Journal of Clinical Oncology</i> , 2014, 32, 2031-2031.	0.8	2
132	A comparative study of circulating biomarkers of anti-VEGF therapy in phase II trials in advanced hepatocellular carcinoma (HCC) patients (pts).. <i>Journal of Clinical Oncology</i> , 2014, 32, 2543-2543.	0.8	1
133	Antiangiogenesis. , 2014, , 262-268.		0
134	Antiangiogenesis. , 2014, , 1-8.		0
135	A phase II trial of cabozantinib in patients with carcinoid and pancreatic neuroendocrine tumors.. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS4157-TPS4157.	0.8	0
136	Abstract IA17: Targeting placental growth factor/ neuropilin-1 pathway inhibits growth and spread of medulloblastoma. , 2014, , .		0
137	Magnetic resonance imaging biomarkers in hepatocellular carcinoma: association with response and circulating biomarkers after sunitinib therapy. <i>Journal of Hematology and Oncology</i> , 2013, 6, 51.	6.9	47
138	A Phase II and Biomarker Study of Ramucirumab, a Human Monoclonal Antibody Targeting the VEGF Receptor-2, as First-Line Monotherapy in Patients with Advanced Hepatocellular Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 6614-6623.	3.2	139
139	Benefits of Vascular Normalization Are Dose and Time Dependentâ€”Letter. <i>Cancer Research</i> , 2013, 73, 7144-7146.	0.4	89
140	Targeting Placental Growth Factor/Neuropilin 1 Pathway Inhibits Growth and Spread of Medulloblastoma. <i>Cell</i> , 2013, 152, 1065-1076.	13.5	209
141	Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastoma. <i>Neuro-Oncology</i> , 2013, 15, 1079-1087.	0.6	205
142	Can We Identify Predictive Biomarkers for Antiangiogenic Therapy of Cancer Using Mathematical Modeling?. <i>Journal of the National Cancer Institute</i> , 2013, 105, 762-765.	3.0	15
143	Effects of Vascular-Endothelial Protein Tyrosine Phosphatase Inhibition on Breast Cancer Vasculature and Metastatic Progression. <i>Journal of the National Cancer Institute</i> , 2013, 105, 1188-1201.	3.0	101
144	Efficacy, Safety, Pharmacokinetics, and Biomarkers of Cediranib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study. <i>Clinical Cancer Research</i> , 2013, 19, 1557-1566.	3.2	65

#	ARTICLE	IF	CITATIONS
145	Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 19059-19064.	3.3	303
146	Generation of functionally competent and durable engineered blood vessels from human induced pluripotent stem cells. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 12774-12779.	3.3	137
147	Vascular Normalization as an Emerging Strategy to Enhance Cancer Immunotherapy. Cancer Research, 2013, 73, 2943-2948.	0.4	535
148	Abstract LB-344: Vascular normalization as an emerging strategy to enhance cancer immunotherapy.. Cancer Research, 2013, 73, LB-344-LB-344.	0.4	2
149	Abstract A67: Reconditioning the tumor immune microenvironment for a breast cancer vaccine therapy.. , 2013, , .		0
150	Biomarkers of Response and Resistance to Anti-angiogenic Treatment. , 2013, , 181-198.		0
151	Abstract LB-81: A study of circulating biomarkers of angiogenesis and inflammation in ER+ breast cancer (BC) versus triple-negative breast cancer (TNBC) patients enrolled in a phase II study of preoperative treatment with 1 cycle of Bevacizumab followed by standard chemo. , 2013, , .		0
152	Circulating oncometabolite 2-hydroxyglutarate (2HG) as a potential surrogate biomarker in patients with <i>isocitrate dehydrogenase</i> mutant (<i>IDH</i>m) intrahepatic cholangiocarcinoma (ICC).. Journal of Clinical Oncology, 2013, 31, 4125-4125.	0.8	0
153	Genetic, tissue, and plasma biomarkers of outcomes from a prospective study of neoadjuvant short course proton-based chemoradiation for resectable pancreatic ductal adenocarcinoma (PDAC).. Journal of Clinical Oncology, 2013, 31, 4047-4047.	0.8	0
154	Differential changes in tissue biomarkers after bevacizumab (BEV) alone in a neoadjuvant study of BEV and chemotherapy in ER+ breast cancer (BC) versus triple-negative breast cancer (TNBC) patients (pts).. Journal of Clinical Oncology, 2013, 31, 1065-1065.	0.8	0
155	Abstract C1: Functional normalization of the breast cancer vasculature through activation of Tie2 using a vascular-endothelial protein tyrosine phosphatase inhibitor.. Molecular Cancer Therapeutics, 2013, 12, C1-C1.	1.9	1
156	An Exploratory Study of Inflammatory Cytokines as Prognostic Biomarkers in Patients With Ductal Pancreatic Adenocarcinoma. Pancreas, 2012, 41, 1001-1007.	0.5	68
157	Neovascularization After Irradiation: What is the Source of Newly Formed Vessels in Recurring Tumors?. Journal of the National Cancer Institute, 2012, 104, 899-905.	3.0	58
158	An isolated tumor perfusion model in mice. Nature Protocols, 2012, 7, 749-755.	5.5	11
159	A transient parabiosis skin transplantation model in mice. Nature Protocols, 2012, 7, 763-770.	5.5	21
160	Changes in Biomarkers of Inflammation and Angiogenesis During Androgen Deprivation Therapy for Prostate Cancer. Oncologist, 2012, 17, 212-219.	1.9	47
161	Molecular Biomarkers of Response to Antiangiogenic Therapy for Cancer. , 2012, 2012, 1-11.		37
162	Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 17561-17566.	3.3	800

#	ARTICLE	IF	CITATIONS
163	Studying primary tumor-associated fibroblast involvement in cancer metastasis in mice. <i>Nature Protocols</i> , 2012, 7, 756-762.	5.5	17
164	Phase I Study of Cetuximab, Irinotecan, and Vandetanib (ZD6474) as Therapy for Patients with Previously Treated Metastatic Colorectal Cancer. <i>PLoS ONE</i> , 2012, 7, e38231.	1.1	48
165	A phase II study of preoperative (preop) bevacizumab (bev) followed by dose-dense (dd) doxorubicin (A)/cyclophosphamide (C)/paclitaxel (T) in combination with bev in HER2-negative operable breast cancer (BC).. <i>Journal of Clinical Oncology</i> , 2012, 30, 1026-1026.	0.8	9
166	Effect of antiangiogenic therapy on tumor-associated macrophages in recurrent glioblastoma.. <i>Journal of Clinical Oncology</i> , 2012, 30, 2010-2010.	0.8	1
167	Clinical, pharmacodynamic (PD), and pharmacokinetic (PK) evaluation of cediranib in advanced hepatocellular carcinoma (HCC): A phase II study (CTEP 7147).. <i>Journal of Clinical Oncology</i> , 2012, 30, 4112-4112.	0.8	1
168	Effects of Sorafenib on Intra-Tumoral Interstitial Fluid Pressure and Circulating Biomarkers in Patients with Refractory Sarcomas (NCI Protocol 6948). <i>PLoS ONE</i> , 2012, 7, e26331.	1.1	39
169	Going beyond systemic fluoropyrimidines with radiation therapy for rectal cancer: what should be the priority?. <i>Oncology</i> , 2012, 26, 741-3.	0.4	0
170	C-X-C receptor type 4 promotes metastasis by activating p38 mitogen-activated protein kinase in myeloid differentiation antigen (Gr-1)-positive cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 302-307.	3.3	85
171	HCC and angiogenesis: possible targets and future directions. <i>Nature Reviews Clinical Oncology</i> , 2011, 8, 292-301.	12.5	453
172	Safety, Efficacy, and Biomarker Exploration in a Phase II Study of Bevacizumab, Oxaliplatin, and Gemcitabine in Recurrent Malignant Ovarian Carcinoma. <i>Clinical Ovarian Cancer &amp; Other Gynecologic Malignancies</i> , 2011, 4, 26-33.	0.2	21
173	Phase II Study of Neoadjuvant Bevacizumab and Radiotherapy for Resectable Soft Tissue Sarcomas. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 81, 1081-1090.	0.4	77
174	CXCL12 (SDF1)-CXCR4/CXCR7 Pathway Inhibition: An Emerging Sensitizer for Anticancer Therapies?. <i>Clinical Cancer Research</i> , 2011, 17, 2074-2080.	3.2	377
175	Normalization of the Vasculature for Treatment of Cancer and Other Diseases. <i>Physiological Reviews</i> , 2011, 91, 1071-1121.	13.1	1,275
176	Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide. <i>Journal of Neuro-Oncology</i> , 2011, 103, 325-332.	1.4	82
177	Glioblastoma Recurrence after Cediranib Therapy in Patients: Lack of Rebound Revascularization as Mode of Escape. <i>Cancer Research</i> , 2011, 71, 19-28.	0.4	186
178	Exploratory Analysis of Early Toxicity of Sunitinib in Advanced Hepatocellular Carcinoma Patients: Kinetics and Potential Biomarker Value. <i>Clinical Cancer Research</i> , 2011, 17, 918-927.	3.2	29
179	Is vasculogenesis crucial for the regrowth of irradiated tumours?. <i>Nature Reviews Cancer</i> , 2011, 11, 532-532.	12.8	10
180	Endothelial focal adhesion kinase mediates cancer cell homing to discrete regions of the lungs via E-selectin up-regulation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 3725-3730.	3.3	169

#	ARTICLE	IF	CITATIONS
181	Is vasculogenesis crucial for the regrowth of irradiated tumours?. Nature Reviews Cancer, 2011, 11, 532-532.	12.8	11
182	Antiangiogenesis. , 2011, , 203-207.		0
183	Direct evidence for lineage-dependent effects of bone marrow stromal cells on tumor progression. American Journal of Cancer Research, 2011, 1, 144-54.	1.4	21
184	Tumor Microvasculature and Microenvironment: Novel Insights Through Intravital Imaging in Pre-Clinical Models. Microcirculation, 2010, 17, 206-225.	1.0	376
185	Plasma Soluble VEGFR-1 Is a Potential Dual Biomarker of Response and Toxicity for Bevacizumab with Chemoradiation in Locally Advanced Rectal Cancer. Oncologist, 2010, 15, 577-583.	1.9	84
186	A Safety and Survival Analysis of Neoadjuvant Bevacizumab with Standard Chemoradiation in a Phase I/II Study Compared with Standard Chemoradiation in Locally Advanced Rectal Cancer. Oncologist, 2010, 15, 845-851.	1.9	55
187	Premetastatic Lung "Niche" Is Vascular Endothelial Growth Factor Receptor 1 Activation Required?. Cancer Research, 2010, 70, 5670-5673.	0.4	31
188	Malignant cells facilitate lung metastasis by bringing their own soil. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 21677-21682.	3.3	505
189	Biomarkers of Antiangiogenic Therapy: How Do We Move From Candidate Biomarkers to Valid Biomarkers?. Journal of Clinical Oncology, 2010, 28, 183-185.	0.8	52
190	Recruitment of Myeloid but not Endothelial Precursor Cells Facilitates Tumor Regrowth after Local Irradiation. Cancer Research, 2010, 70, 5679-5685.	0.4	253
191	Phase II Study of Cediranib, an Oral Pan"Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent Glioblastoma. Journal of Clinical Oncology, 2010, 28, 2817-2823.	0.8	489
192	Abstract LB-213: Plasma soluble VEGFR1 is a potential dual biomarker of response and toxicity for bevacizumab with chemoradiation in locally advanced rectal cancer. , 2010, , .		0
193	Abstract LB-76: A study of neoadjuvant bevacizumab with standard chemoradiation versus chemoradiation alone in locally advanced rectal cancer. , 2010, , .		0
194	Blockade of VEGFR2 and Not VEGFR1 Can Limit Diet-Induced Fat Tissue Expansion: Role of Local versus Bone Marrow-Derived Endothelial Cells. PLoS ONE, 2009, 4, e4974.	1.1	83
195	Efficacy, Safety, and Potential Biomarkers of Sunitinib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study. Journal of Clinical Oncology, 2009, 27, 3027-3035.	0.8	467
196	Direct Evidence that Bevacizumab, an Anti-VEGF Antibody, Up-regulates SDF1 $\alpha$ , CXCR4, CXCL6, and Neuropilin 1 in Tumors from Patients with Rectal Cancer. Cancer Research, 2009, 69, 7905-7910.	0.4	150
197	Reply to S.J. Faivre et al. Journal of Clinical Oncology, 2009, 27, e251-e252.	0.8	3
198	A "Vascular Normalization Index" as Potential Mechanistic Biomarker to Predict Survival after a Single Dose of Cediranib in Recurrent Glioblastoma Patients. Cancer Research, 2009, 69, 5296-5300.	0.4	369

#	ARTICLE	IF	CITATIONS
199	Edema Control by Cediranib, a Vascular Endothelial Growth Factor Receptor-Targeted Kinase Inhibitor, Prolongs Survival Despite Persistent Brain Tumor Growth in Mice. <i>Journal of Clinical Oncology</i> , 2009, 27, 2542-2552.	0.8	285
200	VEGFR2 <sup>+</sup> PDGFR <sup>+</sup> circulating precursor cells participate in capillary restoration after hyperoxia acute lung injury (HALI). <i>Journal of Cellular and Molecular Medicine</i> , 2009, 13, 3720-3729.	1.6	15
201	Biomarkers of response and resistance to antiangiogenic therapy. <i>Nature Reviews Clinical Oncology</i> , 2009, 6, 327-338.	12.5	541
202	Efficacy, Safety, and Biomarkers of Neoadjuvant Bevacizumab, Radiation Therapy, and Fluorouracil in Rectal Cancer: A Multidisciplinary Phase II Study. <i>Journal of Clinical Oncology</i> , 2009, 27, 3020-3026.	0.8	487
203	VEGFR1-activity-independent metastasis formation. <i>Nature</i> , 2009, 461, E4-E4.	13.7	68
204	Paradoxical Effects of PDGF-BB Overexpression in Endothelial Cells on Engineered Blood Vessels In Vivo. <i>American Journal of Pathology</i> , 2009, 175, 294-302.	1.9	43
205	VEGF inhibitors in the treatment of cerebral edema in patients with brain cancer. <i>Nature Reviews Clinical Oncology</i> , 2009, 6, 229-236.	12.5	175
206	Development of Sunitinib in Hepatocellular Carcinoma: Rationale, Early Clinical Experience, and Correlative Studies. <i>Cancer Journal (Sudbury, Mass )</i> , 2009, 15, 263-268.	1.0	33
207	Visualizing anti-tumor immune responses in vivo. <i>DMM Disease Models and Mechanisms</i> , 2009, 2, 107-110.	1.2	8
208	VEGFR1 Activity Modulates Myeloid Cell Infiltration in Growing Lung Metastases but Is Not Required for Spontaneous Metastasis Formation. <i>PLoS ONE</i> , 2009, 4, e6525.	1.1	48
209	A protocol for a lung neovascularization model in rodents. <i>Nature Protocols</i> , 2008, 3, 378-387.	5.5	10
210	A protocol for phenotypic detection and characterization of vascular cells of different origins in a lung neovascularization model in rodents. <i>Nature Protocols</i> , 2008, 3, 388-397.	5.5	9
211	Differential in vivo potential of endothelial progenitor cells from human umbilical cord blood and adult peripheral blood to form functional long-lasting vessels. <i>Blood</i> , 2008, 111, 1302-1305.	0.6	311
212	Normalization of Tumor Vasculature and Microenvironment. , 2008, , 273-281.		3
213	Normalization of Tumor Vasculature and Microenvironment. , 2008, , 261-276.		2
214	Vascular and Interstitial Biology of Tumors. , 2008, , 105-124.		2
215	Abstract LB-247: A multidisciplinary phase II study of AZD2171 (cediranib), an oral pan-VEGF receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. <i>Cancer Research</i> , 2008, 68, LB-247-LB-247.	0.4	7
216	Abstract LB-304: Evaluation of the effects of anti-VEGF therapy in a multidisciplinary phase I/II study of neoadjuvant bevacizumab with chemoradiation therapy in rectal cancer. , 2008, , .		1

#	ARTICLE	IF	CITATIONS
217	Phenotypic and functional characterization of proangiogenic monocytes. <i>FASEB Journal</i> , 2008, 22, 238.7.	0.2	0
218	Antiangiogenic Therapy for Normalization of Tumor Vasculature and Microenvironment. , 2008, , 577-592.		0
219	Histopathologic findings and establishment of novel tumor lines from spontaneous tumors in FVB/N mice. <i>Comparative Medicine</i> , 2008, 58, 253-63.	0.4	32
220	Antiangiogenics: The Potential Role of Integrating This Novel Treatment Modality With Chemoradiation for Solid Cancers. <i>Journal of Clinical Oncology</i> , 2007, 25, 4033-4042.	0.8	130
221	Complete pathological response to bevacizumab and chemoradiation in advanced rectal cancer. <i>Nature Clinical Practice Oncology</i> , 2007, 4, 316-321.	4.3	52
222	Endothelial cellâ€‘based therapy for hematopoiesis. <i>Blood</i> , 2007, 109, 2272-2273.	0.6	1
223	VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects. <i>Trends in Molecular Medicine</i> , 2007, 13, 223-230.	3.5	124
224	Antiangiogenic agents for the treatment of glioblastoma. <i>Expert Opinion on Investigational Drugs</i> , 2007, 16, 1895-1908.	1.9	26
225	A protocol for phenotypic detection and enumeration of circulating endothelial cells and circulating progenitor cells in human blood. <i>Nature Protocols</i> , 2007, 2, 805-810.	5.5	265
226	Angiogenesis in brain tumours. <i>Nature Reviews Neuroscience</i> , 2007, 8, 610-622.	4.9	1,229
227	AZD2171, a Pan-VEGF Receptor Tyrosine Kinase Inhibitor, Normalizes Tumor Vasculature and Alleviates Edema in Glioblastoma Patients. <i>Cancer Cell</i> , 2007, 11, 83-95.	7.7	1,675
228	Targeted therapy in rectal cancer. <i>Oncology</i> , 2007, 21, 1055-65; discussion 1065, 1070, 1075 passim.	0.4	16
229	American Association for Cancer Research 98th Annual Meeting. Angiogenesis and anti-angiogenesis in cancer. <i>IDrugs: the Investigational Drugs Journal</i> , 2007, 10, 366-9.	0.7	1
230	Lessons from phase III clinical trials on anti-VEGF therapy for cancer. <i>Nature Clinical Practice Oncology</i> , 2006, 3, 24-40.	4.3	968
231	Evidence for incorporation of bone marrowâ€‘derived endothelial cells into perfused blood vessels in tumors. <i>Blood</i> , 2006, 107, 2774-2776.	0.6	141
232	Platelets and platelet adhesion support angiogenesis while preventing excessive hemorrhage. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 855-860.	3.3	308
233	Combined Vascular Endothelial Growth Factorâ€‘Targeted Therapy and Radiotherapy for Rectal Cancer: Theory and Clinical Practice. <i>Seminars in Oncology</i> , 2006, 33, S35-S40.	0.8	84
234	Differential CD146 Expression on Circulating Versus Tissue Endothelial Cells in Rectal Cancer Patients: Implications for Circulating Endothelial and Progenitor Cells As Biomarkers for Antiangiogenic Therapy. <i>Journal of Clinical Oncology</i> , 2006, 24, 1449-1453.	0.8	121

#	ARTICLE	IF	CITATIONS
235	Platelet-derived growth factor receptor- $\hat{1}^2$ in Gorham's disease. <i>Nature Clinical Practice Oncology</i> , 2006, 3, 693-697.	4.3	60
236	Engineering vascularized tissue. <i>Nature Biotechnology</i> , 2005, 23, 821-823.	9.4	712
237	Quantum dots spectrally distinguish multiple species within the tumor milieu in vivo. <i>Nature Medicine</i> , 2005, 11, 678-682.	15.2	419
238	Surrogate Markers for Antiangiogenic Therapy and Dose-Limiting Toxicities for Bevacizumab With Radiation and Chemotherapy: Continued Experience of a Phase I Trial in Rectal Cancer Patients. <i>Journal of Clinical Oncology</i> , 2005, 23, 8136-8139.	0.8	410
239	Pleiotropy of tissue-specific growth factors: from neurons to vessels via the bone marrow. <i>Journal of Clinical Investigation</i> , 2005, 115, 596-598.	3.9	12
240	Differential Transplantability of Tumor-Associated Stromal Cells. <i>Cancer Research</i> , 2004, 64, 5920-5924.	0.4	49
241	Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. <i>Nature Medicine</i> , 2004, 10, 145-147.	15.2	1,852
242	Role of eNOS in neovascularization: NO for endothelial progenitor cells. <i>Trends in Molecular Medicine</i> , 2004, 10, 143-145.	3.5	219
243	The Role of Chromosome 18 Abnormalities in the Progression of Pancreatic Adenocarcinoma. <i>Pancreas</i> , 2004, 28, 311-316.	0.5	11
244	Heme oxygenase-1 accelerates tumor angiogenesis of human pancreatic cancer. <i>Angiogenesis</i> , 2003, 6, 15-24.	3.7	191
245	Role of bone marrow-derived cells in tumor angiogenesis and treatment. <i>Cancer Cell</i> , 2003, 3, 515-516.	7.7	59
246	Restoration of SMAD4 by gene therapy reverses the invasive phenotype in pancreatic adenocarcinoma cells. <i>Oncogene</i> , 2003, 22, 6857-6864.	2.6	92
247	Paracrine Regulation of Angiogenesis and Adipocyte Differentiation During In Vivo Adipogenesis. <i>Circulation Research</i> , 2003, 93, e88-97.	2.0	305
248	Gene Therapy for Pancreatic Cancer Using an Adenovirus Vector Encoding Soluble flt-1 Vascular Endothelial Growth Factor Receptor. <i>Pancreas</i> , 2002, 25, 111-121.	0.5	66
249	Suppression of the tumorigenic phenotype by chromosome 18 transfer into pancreatic cancer cell lines. <i>Genes Chromosomes and Cancer</i> , 2002, 34, 234-242.	1.5	19
250	Gene therapy for pancreatic cancer based on genetic characterization of the disease. <i>Journal of Hepato-Biliary-Pancreatic Surgery</i> , 2002, 9, 32-38.	2.0	14
251	Controlling Tumor Microenvironment by the Antiangiogenesis Strategy. , 2001, , 287-289.		0
252	The Antiangiogenesis Effect of Interleukin 12 During Early Growth of Human Pancreatic Cancer in SCID Mice. <i>Pancreas</i> , 2000, 20, 227-233.	0.5	21

#	ARTICLE	IF	CITATIONS
253	Gene therapy for pancreatic cancer using soluble VEGF receptor. <i>Gastroenterology</i> , 2000, 118, A1040.	0.6	1
254	Anti-angiogenesis effect of p53-target gene, BAI1 on pancreatic cancer. <i>Gastroenterology</i> , 2000, 118, A1043.	0.6	1
255	A nonrandomized phase I and biomarker trial of regorafenib in advanced myeloid malignancies. <i>EJHaem</i> , 0, , .	0.4	0
256	Refining genetic and molecular classifications to facilitate breakthrough treatments in intrahepatic cholangiocarcinoma: are we there yet?. <i>Gut</i> , 0, , gutjnl-2022-327782.	6.1	1